Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.
Dose for dose, AM-715 was at least five times as active as pipemidic acid and nalidixic acid against systemic and urinary bladder-kidney infections in mice.
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D051379:Mice; D009268:Nalidixic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D009539:Nicotinic Acids / Q000627:therapeutic use*; D009643:Norfloxacin; D010876:Pipemidic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000890:Anti-Infective Agents; D009539:Nicotinic Acids; D009268:Nalidixic Acid; D010876:Pipemidic Acid; D009643:Norfloxacin